caroline: great to have you here, jack abraham., we are going to be talking about -- technology. ben oakes, ceo of scribe. that is next. ♪ caroline: let's talk biotech. scribe therapeutics, a platform for genetic medicine has locked in a deal to create generic medicines for neurological, neuromuscular disease. this at the company is getting ready to give a talk later today on the potential of its platform . amid this busy day and afternoon, ben oakes joins us now. remind us what you are telling at this event, the power of this technology. ultimately, what -- ultimately, your ex editor. ben: what we are talking about at the american society for cell and gene therapy weight of today is laying out our crisper by design approach, an approach i have been pioneering with the cofounder of scribe. our approach has been to use holistic molecular engineering for the ability to change these crisper molecular machines at every location to create more active and specific and safer therapeutics. one of our scientists will be laying that out toda